These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 30172963)

  • 21. Parameters influencing the pharmacokinetics/pharmacodynamics of piperacillin/tazobactam in patients with febrile neutropenia and haematological malignancy: a prospective study.
    Benech N; Dumitrescu O; Conrad A; Balsat M; Paubelle E; Ducastelle-Lepretre S; Labussière-Wallet H; Salles G; Cohen S; Goutelle S; Ader F;
    J Antimicrob Chemother; 2019 Sep; 74(9):2676-2680. PubMed ID: 31219562
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of piperacillin and tazobactam in critically Ill patients treated with continuous kidney replacement therapy: A mini-review and population pharmacokinetic analysis.
    Selig DJ; DeLuca JP; Chung KK; Pruskowski KA; Livezey JR; Nadeau RJ; Por ED; Akers KS
    J Clin Pharm Ther; 2022 Aug; 47(8):1091-1102. PubMed ID: 35352374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population pharmacokinetics and pharmacodynamics of piperacillin in critically ill patients during the early phase of sepsis.
    Sukarnjanaset W; Jaruratanasirikul S; Wattanavijitkul T
    J Pharmacokinet Pharmacodyn; 2019 Jun; 46(3):251-261. PubMed ID: 30963365
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population pharmacokinetics of piperacillin/tazobactam in critically ill young children.
    Cies JJ; Shankar V; Schlichting C; Kuti JL
    Pediatr Infect Dis J; 2014 Feb; 33(2):168-73. PubMed ID: 23907263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A pilot study on pharmacokinetic/pharmacodynamic target attainment in critically ill patients receiving piperacillin/tazobactam.
    Martínková J; Malbrain ML; Havel E; Šafránek P; Bezouška J; Kaška M
    Anaesthesiol Intensive Ther; 2016; 48(1):23-8. PubMed ID: 26588478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Covariate determinants of effective dosing regimens for time-dependent beta-lactam antibiotics for critically ill patients.
    Kaska M; Havel E; Selke-Krulichova I; Safranek P; Bezouska J; Martinkova J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2018 Sep; 162(3):219-226. PubMed ID: 29582860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. β-Lactam Dosage Regimens in Septic Patients with Augmented Renal Clearance.
    Jacobs A; Taccone FS; Roberts JA; Jacobs F; Cotton F; Wolff F; Creteur J; Vincent JL; Hites M
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29987138
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Repeated Piperacillin-Tazobactam Plasma Concentration Measurements in Severely Obese Versus Nonobese Critically Ill Septic Patients and the Risk of Under- and Overdosing.
    Jung B; Mahul M; Breilh D; Legeron R; Signe J; Jean-Pierre H; Uhlemann AC; Molinari N; Jaber S
    Crit Care Med; 2017 May; 45(5):e470-e478. PubMed ID: 28240688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population pharmacokinetics of piperacillin/tazobactam in critically ill Korean patients and the effects of extracorporeal membrane oxygenation.
    Kim YK; Kim HS; Park S; Kim HI; Lee SH; Lee DH
    J Antimicrob Chemother; 2022 Apr; 77(5):1353-1364. PubMed ID: 35224630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients.
    Sturm AW; Allen N; Rafferty KD; Fish DN; Toschlog E; Newell M; Waibel B
    Pharmacotherapy; 2014 Jan; 34(1):28-35. PubMed ID: 23864417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic drug monitoring-based dose optimisation of piperacillin/tazobactam to improve outcome in patients with sepsis (TARGET): a prospective, multi-centre, randomised controlled trial.
    Hagel S; Fiedler S; Hohn A; Brinkmann A; Frey OR; Hoyer H; Schlattmann P; Kiehntopf M; Roberts JA; Pletz MW;
    Trials; 2019 Jun; 20(1):330. PubMed ID: 31171029
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emergence of antimicrobial resistance to piperacillin/tazobactam or meropenem in the ICU: Intermittent versus continuous infusion. A retrospective cohort study.
    Dhaese SAM; De Kezel M; Callant M; Boelens J; De Bus L; Depuydt P; De Waele JJ
    J Crit Care; 2018 Oct; 47():164-168. PubMed ID: 30005302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beta-lactam antibiotic concentrations in critically ill patients with standard and adjusted dosages: A prospective observational study.
    Areskog Lejbman I; Torisson G; Resman F; Sjövall F
    Acta Anaesthesiol Scand; 2024 Apr; 68(4):530-537. PubMed ID: 38407447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are Standard Dosing Regimens of Ceftriaxone Adapted for Critically Ill Patients with Augmented Creatinine Clearance?
    Ollivier J; Carrié C; d'Houdain N; Djabarouti S; Petit L; Xuereb F; Legeron R; Biais M; Breilh D
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30602511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is high-dose β-lactam therapy associated with excessive drug toxicity in critically ill patients?
    McDonald C; Cotta MO; Little PJ; McWhinney B; Ungerer JP; Lipman J; Roberts JA
    Minerva Anestesiol; 2016 Sep; 82(9):957-65. PubMed ID: 27054905
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Piperacillin Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children with Normal and Augmented Renal Clearance.
    Béranger A; Benaboud S; Urien S; Moulin F; Bille E; Lesage F; Zheng Y; Genuini M; Gana I; Renolleau S; Hirt D; Tréluyer JM; Oualha M
    Clin Pharmacokinet; 2019 Feb; 58(2):223-233. PubMed ID: 29862466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis.
    Asín-Prieto E; Rodríguez-Gascón A; Trocóniz IF; Soraluce A; Maynar J; Sánchez-Izquierdo JÁ; Isla A
    J Antimicrob Chemother; 2014 Jan; 69(1):180-9. PubMed ID: 23908259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Piperacillin-tazobactam dosing in anuric acute kidney injury patients receiving continuous renal replacement therapy.
    Rungkitwattanakul D; Charoensareerat T; Chaichoke E; Rakamthong T; Srisang P; Pattharachayakul S; Srisawat N; Chaijamorn W
    Semin Dial; 2023; 36(6):468-476. PubMed ID: 36807546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exposure levels and target attainment of piperacillin/tazobactam in adult patients admitted to the intensive care unit: a prospective observational study.
    El-Haffaf I; Marsot A; Hachemi D; Pesout T; Williams V; Smith MA; Albert M; Williamson D
    Can J Anaesth; 2024 Apr; 71(4):511-522. PubMed ID: 38243099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of an extended 4-hour infusion of piperacillin-tazobactam in critically ill patients undergoing continuous renal replacement therapy.
    Awissi DK; Beauchamp A; Hébert E; Lavigne V; Munoz DL; Lebrun G; Savoie M; Fagnan M; Amyot J; Tétreault N; Robitaille R; Varin F; Lavallée C; Pichette V; Leblanc M
    Pharmacotherapy; 2015 Jun; 35(6):600-7. PubMed ID: 26095008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.